Ryan Haumschild, PharmD, MBA, MS; Sandeep Sahay, MD, FCCP; Murali Chakinala, MD, FCCP, and Marius M. Hoeper, MD, discuss how pulmonary arterial hypertension management has evolved with new therapeutic pathways like sotatercept offering reverse remodeling capabilities, requiring individualized treatment approaches that balance disease severity, patient preferences, and economic considerations while emphasizing early diagnosis and aggressive upfront combination therapy to achieve disease remission and reduce long-term healthcare costs.
May 28th 2025EP. 1: Pathophysiology of Pulmonary Arterial Hypertension
Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major therapeutic targets including nitric oxide, endothelin, prostacyclin, and activin signaling inhibition.
May 28th 2025EP. 2: Differential Diagnosis of Pulmonary Arterial Hypertension
Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure being ≤20 mmHg and the need to rule out other causes of pulmonary hypertension.
June 6th 2025EP. 3: Importance of Early Detection and Monitoring for Disease Progression
Panelists discuss how early detection barriers include nonspecific symptoms like progressive dyspnea that are often misattributed to more common conditions, leading to delayed diagnosis and the need for improved diagnostic algorithms using biomarkers and imaging.
June 6th 2025EP. 4: Risk Stratification and the Importance of Patient-Centered Care
Panelists discuss how disease progression monitoring requires integrating multiple data points including symptoms, six-minute walk tests, biomarkers like BNP/NT-proBNP, and imaging studies, with risk stratification tools helping guide treatment decisions while considering individual patient characteristics.
June 12th 2025EP. 5: Strengths and Limitations of Current Therapeutic Options
Panelists discuss how treatment individualization depends on patient-specific factors including age, comorbidities, disease severity, and personal preferences, balancing clinical guidelines with shared decision-making to optimize both efficacy and adherence.
Panelists discuss how current therapeutic strengths include 15 approved treatments with different mechanisms of action that can work synergistically, while limitations involve variable delivery methods and complexity, leading to more aggressive upfront combination therapy approaches.
June 19th 2025EP. 7: Sotatercept for Patients with Pulmonary Arterial Hypertension
Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection criteria based on risk stratification and surgical candidacy.
June 19th 2025EP. 8: The Role of the Prostacyclin Pathway
Panelists discuss how sotatercept represents a paradigm shift as the first activin signaling inhibitor showing dramatic improvements in heavily pretreated patients, with the Stellar and Zenith trials demonstrating significant reductions in clinical worsening and potential for reverse remodeling.
June 26th 2025EP. 9: Important Clinical Considerations for Pulmonary Arterial Hypertension
Panelists discuss how prostacyclin pathway treatments remain important but challenging due to significant side effects and delivery complexity, with sotatercept potentially reducing reliance on parenteral prostacyclins while maintaining their role in high-risk patients with low cardiac output.
June 26th 2025EP. 10: Economic Impact of Pulmonary Arterial Hypertension
Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured treatment approach and close monitoring for complications.
July 3rd 2025EP. 11: Barriers to Care for Patients with Pulmonary Arterial Hypertension
Panelists discuss how healthcare resource utilization is primarily driven by hospitalizations, medication costs, and outpatient monitoring, with early diagnosis and treatment potentially reducing long-term costs by preventing disease progression and avoiding expensive advanced therapies.
July 3rd 2025EP. 12: Utilizing Health Economic Outcomes in Clinical Practice
Panelists discuss how patient financial burden varies significantly by insurance type and often leads to treatment interruptions, while prior authorization barriers create administrative challenges that could be improved through better collaboration between medical and payer communities.
July 10th 2025EP. 13: Outlining the Need for Equitable Access to Care
Panelists discuss how cost-effectiveness analyses of newer therapies like sotatercept show substantial benefits in reducing clinical worsening events and potentially decreasing downstream costs through reduced hospitalizations and transplantations, supporting value-based payment models.
July 10th 2025EP. 14: Final Panelist Thoughts on the Management of Pulmonary Arterial Hypertension
Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients with other forms of pulmonary hypertension and those with significant comorbidities.